Armata Pharmaceuticals (ARMP) Stock Price, News & Analysis

Company Overview

Armata Pharmaceuticals, Inc. is a clinical-stage biotechnology company developing targeted bacteriophage therapies to address antibiotic-resistant bacterial infections. The company’s proprietary platform harnesses naturally occurring viruses that selectively infect and destroy bacterial pathogens, offering a novel approach to combating drug-resistant strains that pose significant challenges in hospital and community settings.

Armata’s pipeline includes phage-based candidates aimed at Pseudomonas aeruginosa, a common cause of hospital-acquired pneumonia and infections in cystic fibrosis patients, as well as Staphylococcus aureus and other priority pathogens. Its lead program, AP-PA02, has advanced into early-stage clinical evaluation, while additional efforts focus on preclinical development of therapies for diabetic foot infections and anthrax prophylaxis. The company collaborates with U.S. government agencies on biodefense and public health initiatives, underscoring the potential utility of its phage platform in addressing both emerging and established bacterial threats.

Founded in 2017 and headquartered in Horsham, Pennsylvania, Armata Pharmaceuticals serves the U.S. market with an eye toward global expansion as clinical data emerge. The company is led by Chairman and Chief Executive Officer George Eliopoulos, whose experience in infectious disease drug development guides Armata’s strategic partnerships and research efforts. Through its innovative biologics approach, Armata aims to deliver safer and more effective treatments for patients facing life-threatening bacterial infections.

Key Stats

• Today's Range: $2.86 to $2.96
• 50-Day Range: $2.04 to $3.00
• 52-Week Range: $0.90 to $3.14
• Volume: 6,009 shs
• Average Volume: 12,437 shs
• Market Capitalization: $106.52 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $9.00
• Consensus Rating: Buy

Armata Pharmaceuticals Stock Analysis - MarketRank™

Armata Pharmaceuticals scored higher than 51% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

Armata Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.

Upside Potential

Armata Pharmaceuticals has a consensus price target of $9.00, representing about 206.1% upside from its current price of $2.94.

Amount of Analyst Coverage

Armata Pharmaceuticals has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Armata Pharmaceuticals are expected to decrease in the coming year, from ($0.95) to ($1.70) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Armata Pharmaceuticals is -2.85, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Armata Pharmaceuticals is -2.85, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.34% of the float of Armata Pharmaceuticals has been sold short.

Short Interest Ratio / Days to Cover

Armata Pharmaceuticals has a short interest ratio ("days to cover") of 2.4, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Armata Pharmaceuticals has recently decreased by 25.66%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Armata Pharmaceuticals does not currently pay a dividend.

Dividend Growth

Armata Pharmaceuticals does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

0.34% of the float of Armata Pharmaceuticals has been sold short.

Short Interest Ratio / Days to Cover

Armata Pharmaceuticals has a short interest ratio ("days to cover") of 2.4, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Armata Pharmaceuticals has recently decreased by 25.66%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 2.0 / 5
• News Sentiment: 0.51

News Sentiment

Armata Pharmaceuticals has a news sentiment score of 0.51. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.92 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 4 news articles for Armata Pharmaceuticals this week, compared to 1 article on an average week.

Search Interest

Only 1 people have searched for ARMP on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Armata Pharmaceuticals insiders have not sold or bought any company stock.

Percentage Held by Insiders

84.50% of the stock of Armata Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Only 3.57% of the stock of Armata Pharmaceuticals is held by institutions.

ARMP Stock Analysis - Frequently Asked Questions

How have ARMP shares performed this year?

Armata Pharmaceuticals' stock was trading at $2.00 at the beginning of 2025. Since then, ARMP stock has increased by 47.0% and is now trading at $2.94.

How were Armata Pharmaceuticals' earnings last quarter?

Armata Pharmaceuticals, Inc. (NYSEAMERICAN:ARMP) issued its earnings results on Tuesday, November, 14th. The company reported ($0.31) EPS for the quarter, topping the consensus estimate of ($0.33) by $0.02. The company earned $1.23 million during the quarter, compared to the consensus estimate of $0.90 million.

Who are Armata Pharmaceuticals' major shareholders?

Top institutional investors of Armata Pharmaceuticals include GSB Wealth Management LLC (0.08%).
View institutional ownership trends.

How do I buy shares of Armata Pharmaceuticals?

Shares of ARMP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Armata Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Armata Pharmaceuticals investors own include VBI Vaccines (VBIV), Altimmune (ALT), Vaxart (VXRT), Pfizer (PFE), Advanced Micro Devices (AMD), Co-Diagnostics (CODX) and Amarin (AMRN).

Company Calendar

• Last Earnings: 11/14/2023
• Today: 9/13/2025
• Next Earnings (Estimated): 11/12/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NYSEAMERICAN
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NYSEAMERICAN:ARMP
• CIK: 921114
• Web: www.armatapharma.com
• Phone: (310) 655-2928
• Fax: 310-665-2963
• Employees: 70
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Armata Pharmaceuticals: $9.00
• High Price Target: $9.00
• Low Price Target: $9.00
• Potential Upside/Downside: +206.1%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 1 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.64)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$18.92 million
• Net Margins: -374.30%
• Pretax Margin: -374.30%
• Return on Equity: N/A
• Return on Assets: -24.00%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.06
• Quick Ratio: 0.06

Sales & Book Value

• Annual Sales: $5.17 million
• Price / Sales: 20.60
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($1.33) per share
• Price / Book: -2.21

Miscellaneous

• Outstanding Shares: 36,230,000
• Free Float: 5,616,000
• Market Cap: $106.52 million
• Optionable: Not Optionable
• Beta: 1.09